{"Symbol": "ATRA", "AssetType": "Common Stock", "Name": "Atara Biotherapeutics Inc", "Description": "Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.", "CIK": "1604464", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, UNITED STATES, 91320", "OfficialSite": "https://www.atarabio.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "32085500", "EBITDA": "44852100", "PERatio": "1.556", "PEGRatio": "0", "BookValue": "-5.08", "DividendPerShare": "None", "DividendYield": "None", "EPS": "2.86", "RevenuePerShareTTM": "12.86", "ProfitMargin": "0.154", "OperatingMarginTTM": "-1.027", "ReturnOnAssetsTTM": "0.309", "ReturnOnEquityTTM": "-20.15", "RevenueTTM": "151930000", "GrossProfitTTM": "71046000", "DilutedEPSTTM": "2.86", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.914", "AnalystTargetPrice": "8.67", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "2", "AnalystRatingHold": "2", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "1.556", "ForwardPE": "3.634", "PriceToSalesRatioTTM": "0.211", "PriceToBookRatio": "1.967", "EVToRevenue": "0.234", "EVToEBITDA": "1.165", "Beta": "-0.417", "52WeekHigh": "19.14", "52WeekLow": "4.2", "50DayMovingAverage": "10.97", "200DayMovingAverage": "11.16", "SharesOutstanding": "7210200", "SharesFloat": "4232000", "PercentInsiders": "20.578", "PercentInstitutions": "46.701", "DividendDate": "None", "ExDividendDate": "None"}